• BioVie disclosed acceptance of an abstract from its SUNRISE-PD study of bezisterim (NE3107) in early Parkinson’s disease for presentation at American Academy of Neurology annual meeting in Chicago on April 18-22, 2026.
• Poster presentation is scheduled for April 20, covering baseline demographics and patient characteristics from enrolled participants.
• Topline SUNRISE-PD results are expected in mid-2026, setting up a near-term catalyst for bezisterim as a potential standalone treatment in patients not yet treated with carbidopa/levodopa.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604140800PRIMZONEFULLFEED9687726) on April 14, 2026, and is solely responsible for the information contained therein.